Cancer Research Technology Limited

Astex Therapeutics Limited

Otsuka Pharmaceutical Company, Limited

Taiho Pharmaceutical Company Limited

Rhian Sara Holvey

Steven Howard

Jeffrey David St Denis

Christopher Norbert Johnson

Gianni Chessari

Ildiko Maria Buck

Kim Louise Hirst

James Daniel Osborne

Benjamin David Cons

Bernard Thomas Golding

David Charles Rees

Ian Robert Hardcastle

Emiliano Tamanini

Dale Robert Mitchell

Joanne Peach

Celine Florence Cano

Duncan Charles Miller

Benjamin Paul Whittaker

David Wyn Watson

Martin Edward Mäntylä Noble

Arwel Lewis

Roger John Griffin

Andrew James Woodhead

James Edward Harvey Day

Christopher Charles Frederick Hamlett

Nicholas John Palmer

Brian Christopher Bishop

Steven Douglas Hiscock

Darren James Dixon

Hideto Fujiwara

John Walter Liebeschuetz

Jonas Calleja Priede

Matthew James Gaunt

Meenakshi Sundaram Shanmugham

David Parry-Jones

Aaron Michael Dumas

David John Nash

Guillaume François Parra

Nicholas Paul Richards

Isabelle Anne Lemasson

David Geoffrey Twigg

Sarah Cully

The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them

The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity

The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pharmaceutical compounds

Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity

Growing community of inventors

Cambridge, United Kingdom

Rhian Sara Holvey